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SUMMARY
The aim of this study was to investigate the epidemiological profile of HPV oropharyngeal
infections in HIV-infected men who have sex with men. A total of 135 subjects were enrolled at
the L. Sacco University Hospital (Milan, Italy) to evaluate their HPV oropharyngeal infection
status at baseline and at a follow-up visit at least 12 months later. HPV DNA was detected from
oropharyngeal swabs using an in-house nested PCR that amplifies a segment of the L1 gene. The
PCR products were then sequenced and genotyped. A greater percentage of high-risk genotypes
was identified compared to low-risk genotypes (13·7% vs. 6·9%, P< 0·05), and two uncommon
alpha-HPV genotypes were detected, i.e. HPV-102 and HPV-114. HPV infection prevalence was
24·4% and the cumulative incidence was 24·1%. During the follow-up period, one case of HPV
infection (HPV-33) persisted, while the overall rate of infection clearance was 58·3%. HPV
oropharyngeal infection was widespread in the cohort examined, and most of the infections were
transient and cleared within 12 months. These results may help to clarify the role of HPV in the
oropharynx and may also improve our understanding of the need to implement preventive
strategies in at-risk populations.
Key words: Alpha-HPV genotypes, HIV-infected MSM, human papillomavirus, oropharyngeal
HPV infection, oropharynx mucosa.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is
classified as the seventh most common cancer world-
wide with around 680 000 new diagnoses each year
[1]. While tobacco and alcohol use are the principal
risk factors that have been identified for head and
neck cancer, human papilloma virus (HPV) has been
aetiologically associated with 20–60% of HNSCC
cases, particularly cases involving the oropharynx
[2]. The incidence of HPV-correlated oropharyngeal
cancers has increased over the past few decades, par-
ticularly in males. In addition, several studies have
reported that individuals infected with human immu-
nodeficiency virus (HIV) have an increased risk of
developing HNSCC, potentially due to the effects of
HIV-related immunosuppression [3, 4].
HPV-16 has been detected in ∼30% of HNSCC
cases, followed by HPV-18 (8·0%) [1]. While the
most common genotypes in HPV-related HNSCC
cases have been reported, information regarding the
patterns of oral HPV genotypes in individuals without
cancer or with pre-cancer lesions are lacking. Some
* Author for correspondence: Dr M. Martinelli, University of
Milan, Department of Biomedical Sciences for Health, Via
C. Pascal 36, 20133, Milan, Italy.
(Email: marianna.martinelli@unimi.it)
Epidemiol. Infect., Page 1 of 7. © Cambridge University Press 2016
doi:10.1017/S0950268816001163
studies suggest that the prevalence of HPV oropharyn-
geal infections (0·9–7·5%) [5] is substantially lower
than that of HPV genital infections in healthy indivi-
duals, yet the prevalence of HPV oropharyngeal infec-
tions is still much higher in HIV-infected subjects [6],
particularly for men who have sex with men (MSM)
[7]. Moreover, limited data are available regarding
the distribution of oropharyngeal HPV types in
MSM. Greater knowledge of the HPV oropharyngeal
infections that affect the MSM population could have
important public health implications, especially for
the identification of possible preventive options for
HPV-related head and neck cancer. HPV screening
and HPV vaccination are two of the preventive
options that are currently being considered.
The aim of this study was to investigate the epi-
demiological profile of HPV oropharyngeal infections
in HIV-infected MSM. Therefore, the pattern of oro-
pharyngeal HPV genotypes circulating in an Italian
cohort of HIV-positive MSM is reported, along with
the prevalence, incidence, and persistence of oropha-
ryngeal HPV infections in this population.
METHODS
Study design and sample collection
Between January 2011 and October 2012, 135 HIV-
positive MSM that consecutively visited the Sexually
Transmitted Diseases (STD) Outpatient Clinic of the
L. Sacco University Hospital (Milan, Italy) for routine
HIV infection monitoring were enrolled in this study.
Each participant was asked to return for a follow-up
control visit at least 12 months later and 70 (51·9%) sub-
jects have attended the visit. At each visit, an oropharyn-
geal swab sample was collected from each participant.
Briefly, for each sample, vigorous scraping of the walls
of the oropharyngeal cavity with a swab that was
rotated twice clockwise and twice anticlockwise was per-
formed. The swabs were subsequently preserved in ster-
ile tubes containing 3 ml phosphate-buffered saline
(PBS), and stored at −20 °C until undergoing testing
at the Virology Laboratories of the Department of
Biomedical Sciences for Health, University of Milan
(Milan, Italy).
HPV DNA detection
To obtain the cellular component of each swab sam-
ple, 1·5 ml of each sample received 3 h centrifugation
at 16 000 g. The entire pellet obtained was dissolved in
500 µl PBS and then stored at −20 °C until nucleic
acid isolation was performed.
DNA was extracted from 500 µl oropharyngeal sam-
ple with a NucliSENS® easyMAG® kit (bioMérieux bv,
France). The concentration and purity of the extrac-
ted DNA was evaluated with a spectrophotometer
(NanoDrop ND-2000/2000C, Thermo Fisher Scientific
Inc., USA).
HPV DNA was detected starting from 10 µl
extracted DNA and using a specific nested polymerase
chain reaction (PCR) assay that amplified a 150 base
pair (bp) segment of the L1 open reading frame using
two primer pairs: ELSI_F/ELSI_R and GP5+/GP6+
[8, 9]. Positive (HPV-16-positive cells, Caski) and
negative (water) control samples were included in
each PCR assay. DNA integrity was assessed with
amplification of a 268-bp fragment from the ubiqui-
tous β-globin gene [10]. Amplified PCR products
were subjected to electrophoresis in a 2% agarose gel
containing ethidium bromide (0·5 µg/ml) and were
compared with DNA Molecular Weight Marker 100
(Sigma-Aldrich, USA). To validate the reproducibility
of this HPV detection method the test was repeated
twice for each sample.
HPV DNA sequencing and genotyping
All amplified HPV DNA fragments were sequenced
using the standard Sanger method, in order to identify
the broadest spectrum of genotypes able to infect the
oral mucosa. This method allows characterization of
the predominant sequence in the sample, thereby pre-
venting potential co-infections to be detected.
Briefly, PCR products ∼150 bp in length obtained
from the nested PCR assays were purified using the
NucleoSpin® Extract II kit (Macherey-Nagel GmbH,
Germany), these were then sequenced with an ABI
PRISM 3100 genetic analyser (Applied Biosystem,
USA). L1 gene nucleotide sequences were aligned
with the reference sequences in GenBank and
Papillomavirus Episteme (https://pave.niaid.nih.gov)
using the public bioinformatics program BLAST
[11, 12] for viral genotype identification.
The International Agency for Research on Cancer
(IARC) has assigned 25 HPV types to a high-risk
clade (HR clade), and these have been subdivided
into three groups [13]. Group 1 includes HPV types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, and
these are considered ‘carcinogenic to humans’. The
genotypes of the other two groups, 2A and 2B, are
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designated as ‘probably carcinogenic to humans’ and
‘possibly carcinogenic to humans’, respectively [13].
Statistical analysis
Prevalence of HPV infection was calculated as the pro-
portion of HPV-positive subjects of the total number of
enrolled patients. An incident infection at follow-up
was defined as the detection of HPV DNA in a subject
HPV negative at baseline. A cleared infection at follow-
up was defined as undetectable HPV DNA in a previ-
ously HPV-positive subject. A persistent HPV infection
was defined as detection of the same HPV genotype at
both baseline and follow-up.
Data are presented as the median [interquartile
range (IQR)] and percentage [with 95% confidence
interval (CI)] as appropriate. Comparisons between
groups were made using the χ2 test or the mid-P
exact test. A P value <0·05 was considered statistically
significant (two-tailed test). All statistical analyses
were performed using OpenEpi software, v. 3.03a [14].
Ethical statement
The study protocol used by the research units involved
was approved by the Ethics Committee of L. Sacco
University Hospital, Milan, Italy. Written informed
consent was obtained from all participants. At enrol-
ment, demographic data and information regarding
the HIV status of each patient were collected.
RESULTS
Spectrum of HPV genotypes infecting the
oropharyngeal mucosa
A total of 205 (135 and 70, at baseline and follow-up,
respectively) oropharyngeal swabs were collected from
HIV-infected MSM and analysed for HPV DNA.
Fifty-one out of 205 samples were HPV DNA posi-
tive. The reproducibility of the HPV DNA detection
method was 100%, since the same positive or negative
result was obtained by repeating each sample twice.
Forty-three out of 51 samples were suitable for
DNA sequencing. Twenty-two distinct HPV geno-
types were identified (Fig. 1). HPV-16 and HPV-33
were most often identified in HR group 1 genotypes,
and HPV-70 in group 2B. HPV-6 and HPV-32 were
the most frequent among the low-risk (LR) genotypes.
Of particular interest was the detection of two recently
identified alpha-HPV genotypes, i.e. HPV-102 and
HPV-114.
Epidemiological profile of oropharyngeal HPV
infections in the study population
Demographic and clinical characteristics of the study
population
The HIV-positive MSM included in this study (N=
135) ranged in age from 23 to 70 years (median 43,
IQR 36–49); 115 (85·2%) were of Italian origin,
whereas the remaining 20 (14·8%) were foreign sub-
jects that were legally residing in Italy. Most patients
(84·5%) were receiving combination antiretroviral
therapy and had an undetectable HIV viral load
(72·1%) and a CD4 cell count >500 cells/μl (55·9%,
median 518 cells/μl).
Prevalence of oropharyngeal HPV infection
At baseline, 33/135 subjects (24·4%, 95% CI 17·8–32·2)
were infected with HPV. The median age of the
HPV-positive subjects was 42 years (IQR 36–51) and
the 35–40 years age group was the most frequently
infected, particularly by HR clade types (Fig. 2). All
HPV-positive patients had a CD4 cell count >200
cells/μl (median 506 cells/μl, IQR 433-574 cells/μl).
The prevalence of infections sustained by HR HPV
types was higher than that by LR HPV types (13·7%
vs. 6·9%, respectively, P< 0·05) (Table 1). Of the
HR HPV infections, HPV-16 and HPV-33 were the
most common, each identified in 3·8% of the study co-
hort; infections with HPV-6 and HPV-32 were the
most prevalent (2·3% each) in LR HPV infections.
Two subjects were infected with two uncommon and
recently identified alpha-HPV genotypes, respectively
HPV-102 and HPV-114. These two genotypes had
not been reported previously in oral mucosa.
Incidence and clearance of oropharyngeal HPV
infection
Seventy out of 135 subjects (51·9%) returned at the
follow-up visit at least 12 months later (median 18·5
months, IQR 12–29). Of these 70 subjects, 12
(17·1%) were positive for HPV DNA at baseline and
58 (82·9%) were negative. Of the latter, 14 subjects
developed an HPV infection during the follow-up
period, with an overall cumulative incidence of
24·1% (95% CI 14·5–36·4). The incidence of HR-
HPV infections was 15·5%, mainly sustained by
HPV-33, HPV-35, and HPV-70.
Of the 12 subjects HPV DNA positive at baseline,
seven cleared the infection, with an overall infection
clearance of 58·3% (95% CI 46·8–91·1). Only one
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subject (8·3%) had a HPV infection that persisted
during the follow-up period, and was sustained by
HPV-33. Finally, four subjects (33·3%), exhibited
an infection sustained by a different HPV genotype
at the follow-up visit compared to that identified at
baseline.
DISCUSSION
Limited data are available regarding the distribution
of oropharyngeal HPV types in HIV-positive subjects,
and more specifically, in HIV-infected MSM.
Knowledge of the distribution of specific HPV types
Fig. 1. HPV genotypes identified from oropharyngeal swab samples collected from the present cohort.
Fig. 2. Distribution of HPV-positive and high-risk (HR) clade HPV-positive MSM by age group.
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in populations at high risk for HNSCC would be very
useful for understanding the need for HPV prevention
strategies. In the present study, a high diffusion of
both HR and LR alpha-HPV infections was detected
in oropharyngeal mucosa samples that were collected
from HIV-infected MSM in an Italian population.
Moreover, a broad range of the HPV genotypes iden-
tified belonged to groups 1, 2, and 3, according to
IARC classification [13].
Previously, mucosal alpha-HPV genotypes were
associated with infections that manifested in the geni-
tal tract [13]. In the present study, mucosal
alpha-HPV genotypes were detected in the collected
oropharyngeal mucosa samples, and these results sug-
gest a possible sexual transmission as a primary route
by which oropharyngeal HPV infections are spread in
HIV-infected MSM.
The use of a DNA sequencing method was useful
for identifying 22 different oral HPV genotypes.
Despite the fact that sequencing does not allow detec-
tion of potential co-infections, this method was chosen
for its ability in identifying all infecting types, includ-
ing those not detected by commercially available kits
and/or rare genotypes.
In the present study, two of the oropharyngeal swab
samples contained uncommon alpha-HPV genotypes,
namely HPV-102 and HPV-114. To our knowledge,
this is the first report of these rare types being
identified in the oropharyngeal tract, although cervical
infections supported by these two genotypes have been
described [15, 16]. This finding seems to strengthen the
hypothesis of HPV transmission through oro-genital
sexual contact.
The percentage of HR genotypes detected in the
present cohort was higher than the percentage of LR
genotypes (P< 0·05), with HPV-16 and HPV-33
being the most commonly identified HR genotypes.
Of the LR genotypes, HPV-6 and HPV-32 were the
most prevalent. Currently, the clinical significance of
oropharyngeal HPV type-specific infections is un-
known, although accumulating evidence supports a
causal role for HPV-16 in a subset of head and neck
cancers [16]. Furthermore, other HR HPV genotypes
have been associated with the development of differ-
ent cancers [17]. Little is also known about the clinical
relevance of LR HPV oropharyngeal infections.
The present study provides evidence that oropha-
ryngeal HPV infections have a relevant epidemiologic-
al impact in HIV-positive MSM. Both the HPV
prevalence (24·4%) and the cumulative incidence
(24·1%) are substantial and are also consistent with
the data reported in other studies conducted in Italy
and in other countries [6, 7, 18–20]. In Northern
Italy, Parisi et al. [18] reported a prevalence of oral
HPV infection of around 20%, and Ong et al. found
a prevalence of 19% in Australian HIV-positive
MSM [20]. Moreover, the cumulative incidence
(15·5%) of the HR infections detected in the present
cohort is similar to the 6-month incidence rate
(14·1%) reported by Mooij et al. in HIV-infected
MSM in The Netherlands [19]. Other studies have
described lower rates of HR infections [6, 20], possibly
due to a lack of suitable sampling and standardization
of HPV testing for this anatomical site.
The results of previous studies have suggested that a
substantial proportion of HPV oropharyngeal infec-
tions clear within 1 or 2 years, and this clearance
period is modestly faster than that reported for ano-
genital infections [6, 18, 20]. This difference in clear-
ance may be due to the characteristics of local
mucosal immunity at these two sites. Only one persist-
ent case of HPV-33 infection was detected during the
Table 1. Prevalence of high-risk and low-risk HPV infections at baseline and follow-up
Baseline (N= 135) Follow-up (N = 70)
Genotyping outcome n % (95% CI) n % (95% CI)
Any HPV 33 24·4 (17·8–32·2) 18 25·7 (16·5–36·9)
HPV genotyped 29 87·9 14 77·8
High-risk HPV 18 13·7 (8·6–20·5) 11 16·7 (9·0–27·1)
Group 1 13 9·9 (5·6–16·0) 8 12·1 (5·8–21·7)
Group 2A 0 0
Group 2B 5 3·8 (1·4–8·3) 3 4·5 (1·2–11·9)
Low-risk HPV 9 6·9 (3·4–12·2) 3 9·1 (3·7–18)
Recently identified (HPV-102, HPV-114) 2 1·5 (0·3–4·9) 0 0
CI, Confidence interval.
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follow-up period in the present study. Thus, it appears
that most HPV oropharyngeal infections are transient
and resolve over a short period of time.
However, the evolution of oropharyngeal HPV
infections needs to be better investigated in future
studies with a larger cohorts and with the use of geno-
typing methods that are able to identify potential
HPV co-infections. A weakness of this study is that
the sequencing method used may have underestimated
type-specific prevalence and incidence. In this regard,
at follow-up four subjects exhibited a HPV infection
sustained by a type different from that detected at
baseline. It is difficult to interpret this result as a
new infection (incident infection), rather than a
change in predominance between two or more infec-
tions simultaneously present in the same subject.
Recent studies have reported that severity of im-
munosuppression is one of the stronger risk factors
for the acquisition of an oral HPV infection [4, 21].
Other risk factors include low CD4 cell counts and
higher HIV viral loads. In the present study, the asso-
ciation between HPV infection and HIV status could
not be evaluated due to the small number of subjects
analysed, most of which were immune-reconstituted
by highly active antiviral therapy.
In conclusion, the results of the present study may
help to clarify the epidemiological impact of oro-
pharyngeal HPV infections in HIV-infected MSM.
Oropharyngeal HPV infection is common in Italian
HIV-positiveMSM, and these infections are associated
with a broad spectrum of genotypes, mostly belonging
to the HR clade. Of note, we found two rare alpha-
types, namely HPV-102 and HPV-114, currently
identified only in the genitalmucosa. This is the first evi-
dence of oropharyngeal infection associated with these
types.
Future studies are needed to investigate the clinical
impact and the natural history of infections related to
HPV genotypes identified in the oropharynx. This will
allow establishment of the necessary specific preven-
tion strategies, both primary and secondary.
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